Retatrutide Guide: What the Phase 2 Data Shows & What Nobody Can Tell You Yet
Retatrutide posted the biggest weight-loss numbers ever seen in a trial — about 24% at 48 weeks — and it is not approved anywhere. That combination has produced enormous grey-market use of an investigational drug, with the community working out dosing in real time. This guide is honest about both halves: what the Phase 2 data genuinely shows, and how much is still unknown.
Also known as LY3437943, GLP-3 RT
Retatrutide quick start
- Route
- Subcutaneous injection, once weekly. There is no commercial product — everything in circulation is research-chemical vial material, often vendor-listed as "GLP-3 RT".
- Dose context
- Community practice starts at 0.5–1 mg weekly and titrates slowly toward 4–8 mg, mirroring the trial design at reduced pace. Phase 2 tested up to 12 mg. Being investigational, there is no label schedule — only the trial protocol and accumulated community caution.
- Measure
- A 20 mg vial in 1.0 mL gives 20 mg/mL — a 1 mg dose is 5 units on a U-100 syringe, a 4 mg dose is 20 units.
- Cycle context
- Unknown territory. Phase 2 ran 48 weeks; nothing beyond that horizon has been published. Regain after stopping is expected to mirror the class.
- Status
- NOT approved anywhere — Phase 3 (TRIUMPH programme) ongoing. Every vial sold today is an unverified research chemical.
Dosing context and schedule
What follows is drawn from the published record and from what the community has settled on. Reference points, not prescriptions — your situation is yours.
| Phase | Dose | Volume | Units (U-100) | Note |
|---|---|---|---|---|
| Weeks 1–4 | 0.5–1 mg/week | 0.03–0.05 mL | 3–5 units | 20 mg vial in 1.0 mL. Community lead-in, below the lowest Phase 2 maintenance arm. |
| Weeks 5–8 | 2 mg/week | 0.10 mL | 10 units | The Phase 2 starting dose for most arms. |
| Weeks 9–16 | 4 mg/week | 0.20 mL | 20 units | The most common community maintenance zone — substantial loss was seen here in trial. |
| Week 17+ | 8 mg/week | 0.40 mL | 40 units | The mid-tier trial dose. The 12 mg top arm adds side-effect load for a margin many judge unnecessary. |
Cycle structures
| Approach | Duration | Review point | Note |
|---|---|---|---|
| Phase 2 design | 48 weeks | Weeks 24 and 48 | The published trial window — the entirety of what is formally known about duration. |
| Community structure | Open-ended | Every 4 weeks | Slow escalation, holding each dose 4+ weeks, staying at the lowest dose that keeps producing loss. |
For women
What people actually run
The converged protocol
Start at 1 mg or lower, hold each step at least 4 weeks, and park at 4–8 mg rather than racing to the trial maximum. Watch resting heart rate — the glucagon arm raises it in a way the rest of the class does not. Treat every new vial as unverified until the first draws prove uneventful.
The community runs retatrutide below trial doses on purpose. Phase 2's 24% figure came from the 12 mg arm, but the 8 mg arm was close behind and the 4 mg arm still outperformed approved drugs — so the practical consensus is that the last few milligrams buy little except side effects.
The heart-rate signal is the one class-atypical thing to actually monitor: Phase 2 showed dose-dependent increases in resting heart rate, peaking mid-trial and partially receding. People with cardiac history have no business self-experimenting here, and a cheap wearable trend line is the minimum diligence for everyone else.
Every vial is grey-market by definition — there is no legitimate supply channel for an unapproved drug. Concentration claims are unverified, and the community's standard advice is to treat the first weeks of any new vial as a re-titration.
The GI playbook transfers from the rest of the class unchanged: protein first, small meals, slow titration, and a step back at any sign the gut is losing.
What the evidence actually says
The honest picture
Be precise about what exists. One Phase 2 trial (NEJM, 2023, 338 adults, 48 weeks) showed a mean weight reduction around 24% at 12 mg — the largest figure ever reported in the class — plus striking early results on liver fat in a substudy. Phase 2 in type 2 diabetes was published the same year. That is real, controlled, peer-reviewed evidence, and it is why the excitement is not hype.
Now the other half. There is no Phase 3 readout, no approval, no label, no agreed titration, no cardiovascular outcomes data, and no safety base beyond a few hundred trial participants — compare semaglutide's tens of thousands. The dose-dependent heart-rate increase is a flagged signal awaiting Phase 3 characterisation. And nothing anyone injects today came from a regulated supply chain, which means the practical risk profile includes every unknown of research-chemical manufacture on top of the drug's own.
Running retatrutide in 2026 means volunteering for the open questions. That is a choice adults make; it should at least be made with the questions in view.
How it is proposed to work
Retatrutide is a triple agonist: GLP-1, GIP and glucagon receptors in one molecule. The GLP-1 and GIP arms work as in tirzepatide — appetite suppression, slowed gastric emptying, glucose-dependent insulin effects.
The glucagon arm is the new ingredient: glucagon receptor agonism increases hepatic energy expenditure and fat oxidation, which is the proposed driver of both the class-leading weight numbers and the liver-fat findings. It is also the likely source of the heart-rate increase — glucagon has direct chronotropic effects.
Triple agonism is a genuine mechanistic step, not a marketing layer, but a mechanism this new has correspondingly little long-term human characterisation. The ~6-day half-life supports weekly dosing.
When to talk to a doctor first
Most people run Retatrutide without incident. These are the specific situations where it is worth a conversation with a clinician before you start — not reasons to rule it out, but reasons to go in with your eyes open.
- Any cardiac history, arrhythmia, or uncontrolled hypertension — the dose-dependent heart-rate increase is the class-atypical signal, and self-experimentation on top of cardiac disease is indefensible.
- Personal or family history of medullary thyroid carcinoma or MEN2 — the class boxed-warning logic applies even without a label to print it on.
- History of pancreatitis — the class signal is assumed to transfer.
- Pregnancy, planning pregnancy, or breastfeeding — an investigational compound with zero reproductive data. The gap IS the answer.
- Anyone unwilling to do bloodwork and monitor heart rate — running an unapproved triple agonist without monitoring is not biohacking, it is guessing.
- Tested athletes — as a non-approved substance it falls under WADA S0.
What to expect
Most of what people notice is mild and settles within the first week or two. The list below is ordered by how often it actually comes up, so you know what is routine and what is worth paying attention to.
Common, and usually settles
- Nausea, worst after escalations — same character as the rest of the class.
- Elevated resting heart rate — dose-dependent, typically a handful of beats per minute, peaking around mid-course in trial data.
- Constipation or diarrhea.
- Fatigue and appetite suppression that can overshoot.
Less common
- Vomiting — titration-speed signal.
- Reflux, burping.
- Injection site reactions.
- Skin sensations (tingling/paresthesia) were reported more than placebo in Phase 2.
Rare — stop and get advice
- Cardiac arrhythmia symptoms — palpitations, chest discomfort, syncope: stop and get assessed.
- Pancreatitis-pattern abdominal pain — same-day assessment.
- Severe dehydration from persistent vomiting.
- And the honest entry: unknown unknowns. A few hundred trial participants cannot surface rare events. That is what Phase 3 is for, and it has not reported.
Known interactions
Interactions involving Retatrutide's drug class that DoseIQ screens for. Each one cites where it comes from — an FDA label section or the published record — because an interaction warning you can't trace is just noise.
Semaglutide, tirzepatide and retatrutide all cut appetite and glucose while the insulin dose was sized for the old intake — the mismatch is how hypos happen.
What to do: Prescribers usually reduce insulin when a GLP-1-class drug starts. Monitor glucose closely and have that conversation.
Source: FDA labels, semaglutide/tirzepatide §7
Sulfonylureas force insulin release regardless of glucose; adding any GLP-1-class drug on top is the classic hypoglycemia setup.
What to do: The sulfonylurea dose is usually reduced or stopped when a GLP-1-class drug starts — ask your prescriber if that conversation hasn't happened.
Source: FDA labels, semaglutide/tirzepatide §7
Growth hormone raises glucose and insulin resistance — it works directly against glucose-lowering medication.
What to do: Fasting glucose and HbA1c are worth tracking; medication doses sometimes need adjusting. Your prescriber should know GH peptides are in the picture.
Source: GH pharmacology; tesamorelin label §7
Even short prednisone courses raise glucose; diabetes control commonly loosens during a course.
What to do: Monitor glucose during the course; prescribers often adjust doses temporarily.
Source: FDA label, prednisone §7
The whole GLP-1 class — semaglutide, tirzepatide, retatrutide — delays gastric emptying, which changes how narrow-margin oral drugs (thyroid, warfarin, the pill) absorb.
What to do: Keep timing consistent, and re-check the relevant lab (TSH, INR) a few weeks after starting or increasing the dose.
Source: FDA labels, GLP-1 class §7
Levothyroxine dosing tracks body weight — significant weight loss on any GLP-1-class drug commonly means the old dose becomes too high.
What to do: Re-check TSH after meaningful weight change rather than waiting for symptoms.
Source: Levothyroxine dosing guidance (weight-based)
Both suppress appetite; together intake can drop genuinely too low without feeling like anything is wrong.
What to do: Track weight and actually eat protein on schedule — hunger stops being a reliable signal on this combination.
Source: Class pharmacology; widely reported in practice
The racing heart that warns of a low is exactly what a beta-blocker suppresses — lows sneak up quietly.
What to do: Anyone on this combination should know sweating remains a reliable warning sign when the heart rate isn't.
Source: FDA label, metoprolol §7
Lithium levels track hydration, and a rough titration week — nausea, vomiting, big drops in intake — concentrates lithium.
What to do: Drink deliberately during dose increases, and treat persistent vomiting as a reason to check a lithium level, not just wait out.
Source: Lithium label (volume depletion); GLP-1 class GI profile
Olanzapine and quetiapine drive weight and glucose up; GLP-1-class drugs are increasingly co-prescribed to counter exactly that.
What to do: Usually intentional — the job here is tracking: fasting glucose, HbA1c and lipids tell you whether the plan is working.
Source: Class pharmacology; current prescribing practice
Reconstitution guide
Retatrutide ships as a lyophilised powder and gets mixed with bacteriostatic water before use. How much water you add sets the concentration, which sets how many syringe units make up each dose. One unit on a U-100 syringe is 0.01 mL — the tables below do the arithmetic for the vial sizes you are most likely to be holding.
20mg vial most common
| Water added | Concentration | 1mg |
|---|---|---|
| 1mL (common) | 20 mg/mL | 0.05 mL 5 units |
| 2mL | 10 mg/mL | 0.10 mL 10 units |
10mg vial
| Water added | Concentration | 1mg |
|---|---|---|
| 1mL (common) | 10 mg/mL | 0.10 mL 10 units |
| 2mL | 5 mg/mL | 0.20 mL 20 units |
Standard steps
- Inspect the vialConfirm the label and that the powder cake is intact. Do not use a cracked or compromised vial.
- Let it reach room temperatureSitting out for a few minutes reduces condensation inside the vial when the seal is broken.
- Disinfect both stoppersWipe the compound vial and the bacteriostatic water vial with a fresh alcohol swab and let them air-dry.
- Draw the bacteriostatic waterUse a sterile syringe to draw the volume you have chosen from the reconstitution table.
- Add the water down the vial wallInject slowly so it runs down the inside wall rather than spraying directly onto the powder. This limits foaming.
- Dissolve gentlySwirl or roll the vial between your hands until the cake dissolves. Never shake — agitation damages peptide bonds. The solution should end up clear.
- Label and refrigerateWrite the reconstitution date and concentration on the vial. Store at 2–8°C. Do not freeze.
Timeline and monitoring
- Weeks 1–8Appetite effect arrives early; weight moves modestly at lead-in doses.
- Weeks 8–24The steep phase — Phase 2 curves at 8–12 mg were among the fastest recorded in the class.
- Weeks 24–48Still falling at trial end — the 48-week curves had not plateaued, which is part of why expectations for Phase 3 are high.
- Beyond 48 weeksNobody knows. That is not rhetoric; the published record simply ends there.
Bloodwork worth discussing
Markers a clinician may consider relevant before or during a protocol. This is context for a conversation, not a self-ordering list.
| Marker | Why it is relevant |
|---|---|
| Resting heart rate (tracked, not lab) | The class-atypical signal. A baseline and a weekly trend line are the minimum. |
| HbA1c and fasting glucose | Baseline metabolic status and progress. |
| Liver panel (ALT/AST) | The liver-fat findings make hepatic markers doubly interesting here. |
| Lipid panel | Expected to improve; document the before. |
| Comprehensive metabolic panel | Renal baseline, dehydration risk as across the class. |
Supplies by cycle length
A 20 mg vial provides 20 weeks at 1 mg, 10 weeks at 2 mg, 5 weeks at 4 mg, or 2–3 weeks at 8 mg.
| Cycle length | Vials | Syringes | BAC water | Planning note |
|---|---|---|---|---|
| First 8 weeks (1→2 mg) | 1 × 20 mg | 8 syringes | 1 × 10 mL bottle | One vial covers the entire lead-in with margin. |
| 12 weeks at 4 mg | 3 × 20 mg | 12 syringes | 1 × 10 mL bottle | The common maintenance zone. |
| 12 weeks at 8 mg | 5 × 20 mg | 12 syringes | 1 × 10 mL bottle | Higher doses double the burn rate — and the unknowns. |
What the research record contains
Phase 2 obesity trial (Jastreboff et al., NEJM 2023, n=338): mean weight reduction of about 24% at 12 mg over 48 weeks; every retatrutide arm beat placebo decisively; curves not yet plateaued at trial end.
Phase 2 type 2 diabetes trial (Rosenstock et al., The Lancet 2023): substantial HbA1c and weight reductions versus placebo and dulaglutide.
Liver-fat substudy: large reductions in hepatic fat fraction, with a majority of higher-dose participants reaching normal liver fat.
Phase 3 (TRIUMPH programme): ongoing. Until it reads out and an approval follows, every safety and durability statement is provisional.
Storage and handling
- Lyophilised vials: refrigerate at 2–8°C, dark and dry.
- Reconstituted: refrigerate, use within 28–30 days with bacteriostatic water, never freeze.
- Label date and concentration. With no commercial product to anchor expectations, YOUR label is the only record of what is in the vial.
Troubleshooting
My resting heart rate is up 10+ bpm.
That is above the typical trial-observed bump. Hold or reduce the dose and let it settle; if it persists or comes with palpitations or chest symptoms, stop and see a clinician. This is the one side effect in the class you should not wait out at a higher dose.
How fast can I titrate up?
The community answer: slower than you want to. Four weeks per step minimum, and the loss at 4 mg is already beyond what approved drugs average — speed buys side effects, not results.
My vendor's "GLP-3 RT" vial seems weaker than my last one.
With unverified supply, batch variation is expected — in either direction. Re-titrate conservatively on every new source, and treat any dramatic difference as a data point about the vendor, not about your biology.
I missed a week.
Resume at the same dose on your normal day. After two or more missed weeks, step back one dose level before resuming — the adaptation fades.
Regulatory status
Not approved by the FDA or any other regulator, for any indication. Phase 3 trials are ongoing.
There is no lawful compounding pathway for an unapproved drug — all vial product is sold as "research use only" material, a seller's legal position that guarantees nothing about content.
As a non-approved substance, it is prohibited in sport under WADA S0.
How it compares
| Compared with | Difference that matters |
|---|---|
| Tirzepatide | Retatrutide's Phase 2 average beats tirzepatide's Phase 3 average (~24% vs ~21%) — but one has an FDA label, pharmacovigilance and verified supply, and the other has none of those. For most people the honest comparison ends there. |
| Semaglutide | Bigger numbers, smaller evidence base, no outcomes data against semaglutide's SELECT trial. Semaglutide is the conservative choice in every sense. |
Frequently asked questions
Is retatrutide the strongest weight-loss drug?
On trial averages published so far, yes. But "strongest in Phase 2" and "best characterised" are different claims — the second belongs to semaglutide and tirzepatide by miles.
When will it be approved?
Phase 3 is ongoing; approval, if it comes, follows the readout. Nobody outside the sponsor knows the date, and any vendor claiming otherwise is selling.
Why is my heart rate up?
The glucagon-receptor arm — it has direct heart-rate effects the pure GLP-1-class drugs mostly lack. Dose-dependent, and the reason cardiac history is a hard exclusion.
Is grey-market retatrutide real?
Testing services have found both accurate and inaccurate vials in circulation. Without a COA from an independent lab tied to YOUR batch, the honest answer for any given vial is: unverified. DoseIQ's batch vault exists for exactly this record-keeping.
Should I just wait for approval?
That is the conservative play, and semaglutide and tirzepatide exist now with full labels. The case for waiting writes itself; the case for not waiting is a personal risk decision this page can inform but should not make for you.
References
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2Jastreboff et al., New England Journal of Medicine, 2023
- Retatrutide in Type 2 Diabetes — Phase 2Rosenstock et al., The Lancet, 2023
- WADA Prohibited List — S0 Non-Approved SubstancesWorld Anti-Doping Agency
This page is an educational research reference and is not medical advice. Retatrutide is not approved for human use in any jurisdiction. Dose figures reflect the published record and what the community has converged on — starting points to weigh, not instructions. Consult a qualified healthcare provider before starting any protocol.